Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial


ÖZKAN M., GÜNDÜZ S., GÜRSOY O. M. , KARAKOYUN S., ASTARCIOĞLU M. A. , KALÇIK M., et al.

AMERICAN HEART JOURNAL, cilt.170, ss.409-419, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 170 Konu: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.ahj.2015.04.025
  • Dergi Adı: AMERICAN HEART JOURNAL
  • Sayfa Sayısı: ss.409-419

Özet

Background Low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator (t-PA) with repetition as needed has been shown to provide effective and safer thrombolysis in patients with prosthetic valve thrombosis (PVT). Further prolonging the infusion time may be rational with regard to reducing complication rates without reducing success rates. We aimed to investigate the efficacy and safety of ultraslow (25 hours) infusion of low-dose (25 mg) alteplase (t-PA) for PVT.